Please login to the form below

Not currently logged in
Email:
Password:

Gamida Cell strengthens leadership team

Appoints Josh Hamermesh and Paul Nee

Josh HamermeshCellular and immune therapeutics group Gamida Cell has appointed a new chief business officer in the form of Josh Hamermesh.

Hamermesh (pictured right), who joins from Locust Walk Partners where he served as senior vice president, will lead the business operations and corporate development strategies for the company.

He has also served as vice president, business and corporate development at Infinity Pharmaceuticals, where he was responsible for the company’s in-licensing, out-licensing and alliance management activities.

Paul NeeAlongside Hamermesh, Gamida Cell has appointed Paul Nee (pictured left) as its vice president of marketing.

Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.

Julian Adams, chairman and chief executive officer of Gamida Cell, said: “We are pleased to welcome Josh and Paul to the Gamida Cell leadership team.

“Their combined experience in corporate strategy, business development and commercialisation will be invaluable to the company’s continued growth as we advance our clinical programmes in blood cancers and rare genetic diseases.”

4th May 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics